Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Clinical trial NCT07448324 · RECRUITING
Trial details
- NCT number
- NCT07448324
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2028-01-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.